Oghuzan Atay, co-founder and CEO of BillionToOne

Pre­ci­sion di­ag­nos­tics biotech wins newest round of in­vestor back­ing in bid to fa­cil­i­tate com­pa­ny ex­pan­sion

Di­ag­nos­tics firm Bil­lion­ToOne raised $55 mil­lion in a Se­ries B last year in a bid to ex­pand the com­pa­ny, which mar­kets a pre­na­tal screen­ing test. Nine months lat­er, thanks to some more in­vestors, the com­pa­ny of­fi­cial­ly has more mon­ey in its war chest to work with.

The Cal­i­for­nia di­ag­nos­tics com­pa­ny an­nounced an over­sub­scribed Se­ries C ear­ly this morn­ing, net­ting $125 mil­lion in its largest raise to date. That raise comes from a range of in­vestors, co-led by Adams Street Part­ners and Hum­ming­bird Ven­tures. A few oth­er in­vestors in­clude Nor­west Ven­ture Part­ners, Fifty Years VC and Lib­er­tus Cap­i­tal.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.